Does the media favor ROIV or REGN?

In the previous week, Regeneron Pharmaceuticals had 35 more articles in the media than Roivant Sciences. MarketBeat recorded 53 mentions for Regeneron Pharmaceuticals and 18 mentions for Roivant Sciences. Roivant Sciences' average media sentiment score of 1.08 beat Regeneron Pharmaceuticals' score of 0.41 indicating that Roivant Sciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Roivant Sciences 10 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Regeneron Pharmaceuticals 13 Very Positive mention(s) 2 Positive mention(s) 33 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Neutral

Which has preferable earnings & valuation, ARGX or ROIV?

argenex has higher revenue and earnings than Roivant Sciences. Roivant Sciences is trading at a lower price-to-earnings ratio than argenex, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio argenex $4.25B 12.74 $1.29B $26.04 33.22 Roivant Sciences $7.53M 3,470.30 -$299.77M -$0.53 N/A

Is ARGX or ROIV more profitable?

argenex has a net margin of 32.19% compared to Roivant Sciences' net margin of -3,534.96%. argenex's return on equity of 43.59% beat Roivant Sciences' return on equity. Company Net Margins Return on Equity Return on Assets argenex 32.19% 43.59% 36.66% Roivant Sciences -3,534.96% -22.94% -21.53%

Does the media prefer ARGX or ROIV?

In the previous week, Roivant Sciences had 8 more articles in the media than argenex. MarketBeat recorded 18 mentions for Roivant Sciences and 10 mentions for argenex. Roivant Sciences' average media sentiment score of 1.08 beat argenex's score of 0.92 indicating that Roivant Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment argenex 4 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Roivant Sciences 10 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to RVMD or ROIV?

In the previous week, Revolution Medicines had 5 more articles in the media than Roivant Sciences. MarketBeat recorded 23 mentions for Revolution Medicines and 18 mentions for Roivant Sciences. Roivant Sciences' average media sentiment score of 1.08 beat Revolution Medicines' score of 0.62 indicating that Roivant Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Revolution Medicines 12 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Positive Roivant Sciences 10 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings and valuation, ROIV or NTRA?

Natera has higher revenue and earnings than Roivant Sciences. Natera is trading at a lower price-to-earnings ratio than Roivant Sciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Roivant Sciences $7.53M 3,470.30 -$299.77M -$0.53 N/A Natera $2.31B 20.00 -$208.16M -$1.63 N/A

Is ROIV or NTRA more profitable?

Natera has a net margin of -7.11% compared to Roivant Sciences' net margin of -3,534.96%. Natera's return on equity of -11.82% beat Roivant Sciences' return on equity. Company Net Margins Return on Equity Return on Assets Roivant Sciences -3,534.96% -22.94% -21.53% Natera -7.11% -11.82% -8.19%

Does the media favor ROIV or NTRA?

In the previous week, Natera had 18 more articles in the media than Roivant Sciences. MarketBeat recorded 36 mentions for Natera and 18 mentions for Roivant Sciences. Roivant Sciences' average media sentiment score of 1.08 beat Natera's score of 0.71 indicating that Roivant Sciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Roivant Sciences 10 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Natera 16 Very Positive mention(s) 4 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive

Which has stronger earnings & valuation, BIIB or ROIV?

Biogen has higher revenue and earnings than Roivant Sciences. Roivant Sciences is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Biogen $9.89B 3.11 $1.29B $5.65 36.80 Roivant Sciences $7.53M 3,470.30 -$299.77M -$0.53 N/A

Is BIIB or ROIV more profitable?

Biogen has a net margin of 8.32% compared to Roivant Sciences' net margin of -3,534.96%. Biogen's return on equity of 11.18% beat Roivant Sciences' return on equity. Company Net Margins Return on Equity Return on Assets Biogen 8.32% 11.18% 6.88% Roivant Sciences -3,534.96% -22.94% -21.53%

Does the media refer more to BIIB or ROIV?

In the previous week, Biogen and Biogen both had 18 articles in the media. Roivant Sciences' average media sentiment score of 1.08 beat Biogen's score of 0.99 indicating that Roivant Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Biogen 10 Very Positive mention(s) 4 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Roivant Sciences 10 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Roivant Sciences (ROIV) Competitors

$36.34 +1.22 (+3.47%)

Closing price 08/7/2026 04:00 PM Eastern

Extended Trading

$35.08 -1.27 (-3.48%)

As of 08/7/2026 07:48 PM Eastern

Compare

ROIV vs. REGN, ARGX, RVMD, NTRA, and BIIB

Should you buy Roivant Sciences stock or one of its competitors? MarketBeat compares Roivant Sciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Roivant Sciences include Regeneron Pharmaceuticals (REGN), argenex (ARGX), Revolution Medicines (RVMD), Natera (NTRA), and Biogen (BIIB). These companies are all part of the "biotechnology" industry.

How does Roivant Sciences compare to Regeneron Pharmaceuticals?

Roivant Sciences (NASDAQ:ROIV) and Regeneron Pharmaceuticals (NASDAQ:REGN) are both large-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, earnings, dividends, valuation, institutional ownership, profitability and risk.

Regeneron Pharmaceuticals has a net margin of 27.86% compared to Roivant Sciences' net margin of -3,534.96%. Regeneron Pharmaceuticals' return on equity of 13.47% beat Roivant Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Roivant Sciences	-3,534.96%	-22.94%	-21.53%
Regeneron Pharmaceuticals	27.86%	13.47%	10.34%

Regeneron Pharmaceuticals has higher revenue and earnings than Roivant Sciences. Roivant Sciences is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Roivant Sciences	$7.53M	3,470.30	-$299.77M	-$0.53	N/A
Regeneron Pharmaceuticals	$14.34B	5.63	$4.50B	$40.46	19.39

Roivant Sciences has a beta of 1.12, suggesting that its share price is 12% more volatile than the broader market. Comparatively, Regeneron Pharmaceuticals has a beta of 0.21, suggesting that its share price is 79% less volatile than the broader market.

Roivant Sciences currently has a consensus price target of $34.77, suggesting a potential downside of 4.31%. Regeneron Pharmaceuticals has a consensus price target of $797.75, suggesting a potential upside of 1.71%. Given Regeneron Pharmaceuticals' higher probable upside, analysts plainly believe Regeneron Pharmaceuticals is more favorable than Roivant Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Roivant Sciences	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.83
Regeneron Pharmaceuticals	0 Sell rating(s)	10 Hold rating(s)	16 Buy rating(s)	1 Strong Buy rating(s)	2.67

64.8% of Roivant Sciences shares are held by institutional investors. Comparatively, 83.3% of Regeneron Pharmaceuticals shares are held by institutional investors. 8.8% of Roivant Sciences shares are held by insiders. Comparatively, 7.0% of Regeneron Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, Regeneron Pharmaceuticals had 35 more articles in the media than Roivant Sciences. MarketBeat recorded 53 mentions for Regeneron Pharmaceuticals and 18 mentions for Roivant Sciences. Roivant Sciences' average media sentiment score of 1.08 beat Regeneron Pharmaceuticals' score of 0.41 indicating that Roivant Sciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Roivant Sciences	10 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Regeneron Pharmaceuticals	13 Very Positive mention(s)	2 Positive mention(s)	33 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Neutral

Summary

Regeneron Pharmaceuticals beats Roivant Sciences on 11 of the 16 factors compared between the two stocks.

How does Roivant Sciences compare to argenex?

argenex (NASDAQ:ARGX) and Roivant Sciences (NASDAQ:ROIV) are both large-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their risk, analyst recommendations, institutional ownership, earnings, valuation, dividends, profitability and media sentiment.

In the previous week, Roivant Sciences had 8 more articles in the media than argenex. MarketBeat recorded 18 mentions for Roivant Sciences and 10 mentions for argenex. Roivant Sciences' average media sentiment score of 1.08 beat argenex's score of 0.92 indicating that Roivant Sciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
argenex	4 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Roivant Sciences	10 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

60.3% of argenex shares are held by institutional investors. Comparatively, 64.8% of Roivant Sciences shares are held by institutional investors. 2.4% of argenex shares are held by company insiders. Comparatively, 8.8% of Roivant Sciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

argenex has a net margin of 32.19% compared to Roivant Sciences' net margin of -3,534.96%. argenex's return on equity of 43.59% beat Roivant Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
argenex	32.19%	43.59%	36.66%
Roivant Sciences	-3,534.96%	-22.94%	-21.53%

argenex has higher revenue and earnings than Roivant Sciences. Roivant Sciences is trading at a lower price-to-earnings ratio than argenex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
argenex	$4.25B	12.74	$1.29B	$26.04	33.22
Roivant Sciences	$7.53M	3,470.30	-$299.77M	-$0.53	N/A

argenex presently has a consensus price target of $1,056.89, suggesting a potential upside of 22.18%. Roivant Sciences has a consensus price target of $34.77, suggesting a potential downside of 4.31%. Given argenex's stronger consensus rating and higher probable upside, equities analysts clearly believe argenex is more favorable than Roivant Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
argenex	0 Sell rating(s)	4 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	2.92
Roivant Sciences	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.83

argenex has a beta of 0.46, indicating that its share price is 54% less volatile than the broader market. Comparatively, Roivant Sciences has a beta of 1.12, indicating that its share price is 12% more volatile than the broader market.

Summary

argenex beats Roivant Sciences on 11 of the 17 factors compared between the two stocks.

How does Roivant Sciences compare to Revolution Medicines?

Revolution Medicines (NASDAQ:RVMD) and Roivant Sciences (NASDAQ:ROIV) are both large-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, profitability, valuation, institutional ownership, dividends, risk and earnings.

Roivant Sciences has lower revenue, but higher earnings than Revolution Medicines. Roivant Sciences is trading at a lower price-to-earnings ratio than Revolution Medicines, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Revolution Medicines	$11.58M	3,797.22	-$1.13B	-$8.82	N/A
Roivant Sciences	$7.53M	3,470.30	-$299.77M	-$0.53	N/A

94.3% of Revolution Medicines shares are owned by institutional investors. Comparatively, 64.8% of Roivant Sciences shares are owned by institutional investors. 7.6% of Revolution Medicines shares are owned by insiders. Comparatively, 8.8% of Roivant Sciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Revolution Medicines has a net margin of 0.00% compared to Roivant Sciences' net margin of -3,534.96%. Roivant Sciences' return on equity of -22.94% beat Revolution Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Revolution Medicines	N/A	-88.20%	-57.85%
Roivant Sciences	-3,534.96%	-22.94%	-21.53%

Revolution Medicines has a beta of 1.39, suggesting that its stock price is 39% more volatile than the broader market. Comparatively, Roivant Sciences has a beta of 1.12, suggesting that its stock price is 12% more volatile than the broader market.

Revolution Medicines currently has a consensus target price of $153.05, suggesting a potential downside of 25.39%. Roivant Sciences has a consensus target price of $34.77, suggesting a potential downside of 4.31%. Given Roivant Sciences' higher probable upside, analysts clearly believe Roivant Sciences is more favorable than Revolution Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Revolution Medicines	1 Sell rating(s)	1 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	2.95
Roivant Sciences	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.83

In the previous week, Revolution Medicines had 5 more articles in the media than Roivant Sciences. MarketBeat recorded 23 mentions for Revolution Medicines and 18 mentions for Roivant Sciences. Roivant Sciences' average media sentiment score of 1.08 beat Revolution Medicines' score of 0.62 indicating that Roivant Sciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Revolution Medicines	12 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Positive
Roivant Sciences	10 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Revolution Medicines beats Roivant Sciences on 9 of the 16 factors compared between the two stocks.

How does Roivant Sciences compare to Natera?

Roivant Sciences (NASDAQ:ROIV) and Natera (NASDAQ:NTRA) are both large-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, valuation, dividends, earnings, risk, media sentiment, analyst recommendations and institutional ownership.

Natera has higher revenue and earnings than Roivant Sciences. Natera is trading at a lower price-to-earnings ratio than Roivant Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Roivant Sciences	$7.53M	3,470.30	-$299.77M	-$0.53	N/A
Natera	$2.31B	20.00	-$208.16M	-$1.63	N/A

In the previous week, Natera had 18 more articles in the media than Roivant Sciences. MarketBeat recorded 36 mentions for Natera and 18 mentions for Roivant Sciences. Roivant Sciences' average media sentiment score of 1.08 beat Natera's score of 0.71 indicating that Roivant Sciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Roivant Sciences	10 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Natera	16 Very Positive mention(s)	4 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

64.8% of Roivant Sciences shares are held by institutional investors. Comparatively, 99.9% of Natera shares are held by institutional investors. 8.8% of Roivant Sciences shares are held by company insiders. Comparatively, 5.1% of Natera shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Roivant Sciences presently has a consensus target price of $34.77, suggesting a potential downside of 4.31%. Natera has a consensus target price of $299.65, suggesting a potential downside of 6.97%. Given Roivant Sciences' stronger consensus rating and higher possible upside, research analysts clearly believe Roivant Sciences is more favorable than Natera.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Roivant Sciences	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.83
Natera	2 Sell rating(s)	3 Hold rating(s)	15 Buy rating(s)	2 Strong Buy rating(s)	2.77

Roivant Sciences has a beta of 1.12, suggesting that its stock price is 12% more volatile than the broader market. Comparatively, Natera has a beta of 1.51, suggesting that its stock price is 51% more volatile than the broader market.

Natera has a net margin of -7.11% compared to Roivant Sciences' net margin of -3,534.96%. Natera's return on equity of -11.82% beat Roivant Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Roivant Sciences	-3,534.96%	-22.94%	-21.53%
Natera	-7.11%	-11.82%	-8.19%

Summary

Natera beats Roivant Sciences on 10 of the 17 factors compared between the two stocks.

How does Roivant Sciences compare to Biogen?

Biogen (NASDAQ:BIIB) and Roivant Sciences (NASDAQ:ROIV) are both large-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, earnings, valuation, dividends, institutional ownership, media sentiment, profitability and risk.

In the previous week, Biogen and Biogen both had 18 articles in the media. Roivant Sciences' average media sentiment score of 1.08 beat Biogen's score of 0.99 indicating that Roivant Sciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Biogen	10 Very Positive mention(s)	4 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Roivant Sciences	10 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Biogen currently has a consensus target price of $224.61, indicating a potential upside of 8.02%. Roivant Sciences has a consensus target price of $34.77, indicating a potential downside of 4.31%. Given Biogen's higher possible upside, equities research analysts plainly believe Biogen is more favorable than Roivant Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biogen	1 Sell rating(s)	13 Hold rating(s)	17 Buy rating(s)	1 Strong Buy rating(s)	2.56
Roivant Sciences	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.83

87.9% of Biogen shares are owned by institutional investors. Comparatively, 64.8% of Roivant Sciences shares are owned by institutional investors. 0.3% of Biogen shares are owned by insiders. Comparatively, 8.8% of Roivant Sciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Biogen has higher revenue and earnings than Roivant Sciences. Roivant Sciences is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biogen	$9.89B	3.11	$1.29B	$5.65	36.80
Roivant Sciences	$7.53M	3,470.30	-$299.77M	-$0.53	N/A

Biogen has a beta of 0.17, meaning that its stock price is 83% less volatile than the broader market. Comparatively, Roivant Sciences has a beta of 1.12, meaning that its stock price is 12% more volatile than the broader market.

Biogen has a net margin of 8.32% compared to Roivant Sciences' net margin of -3,534.96%. Biogen's return on equity of 11.18% beat Roivant Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biogen	8.32%	11.18%	6.88%
Roivant Sciences	-3,534.96%	-22.94%	-21.53%

Summary

Biogen beats Roivant Sciences on 10 of the 15 factors compared between the two stocks.

Get Roivant Sciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ROIV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ROIV vs. The Competition

Export

Metric	Roivant Sciences	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$26.14B	$3.69B	$7.01B	$13.00B
Dividend Yield	N/A	3.76%	2.58%	10.20%
P/E Ratio	-68.57	9.02	271.11	25.19
Price / Sales	3,470.30	1,351.04	611.67	94.90
Price / Cash	N/A	102.35	71.81	50.72
Price / Book	4.94	18.10	13.25	6.22
Net Income	-$299.77M	-$13.25M	$3.45B	$342.66M
7 Day Performance	7.17%	6.24%	4.67%	4.41%
1 Month Performance	-1.28%	-3.50%	-1.28%	-1.11%
1 Year Performance	216.28%	61.28%	77.33%	23.99%

Roivant Sciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ROIV Roivant Sciences	1.6254 of 5 stars	$36.34 +3.5%	$34.77 -4.3%	+216.3%	$26.14B	$7.53M	N/A	860	Trending News Analyst Forecast
REGN Regeneron Pharmaceuticals	3.3498 of 5 stars	$759.24 -0.4%	$797.75 +5.1%	+39.3%	$80.63B	$14.34B	18.77	15,410	Trending News
ARGX argenex	4.5072 of 5 stars	$830.79 -2.7%	$1,056.89 +27.2%	+30.7%	$53.42B	$4.25B	31.90	1,863	Analyst Forecast
RVMD Revolution Medicines	1.5975 of 5 stars	$182.45 -2.7%	$144.67 -20.7%	+486.1%	$39.87B	$11.58M	N/A	250	News Coverage Earnings Report Analyst Forecast
NTRA Natera	2.9336 of 5 stars	$270.36 +1.0%	$267.83 -0.9%	+112.0%	$38.35B	$2.50B	N/A	6,140	Trending News Earnings Report Analyst Forecast Insider Trade Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ROIV) was last updated on 8/9/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Roivant Sciences (ROIV) Competitors

ROIV vs. REGN, ARGX, RVMD, NTRA, and BIIB

How does Roivant Sciences compare to Regeneron Pharmaceuticals?

Summary

How does Roivant Sciences compare to argenex?

Summary

How does Roivant Sciences compare to Revolution Medicines?

Summary

How does Roivant Sciences compare to Natera?

Summary

How does Roivant Sciences compare to Biogen?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ROIV vs. The Competition

Roivant Sciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Roivant Sciences (ROIV) Competitors

ROIV vs. REGN, ARGX, RVMD, NTRA, and BIIB

How does Roivant Sciences compare to Regeneron Pharmaceuticals?

Is ROIV or REGN more profitable?

Which has preferable valuation & earnings, ROIV or REGN?

Which has more risk & volatility, ROIV or REGN?

Do analysts prefer ROIV or REGN?

Do institutionals & insiders hold more shares of ROIV or REGN?

Does the media favor ROIV or REGN?

Summary

How does Roivant Sciences compare to argenex?

Does the media prefer ARGX or ROIV?

Do insiders and institutionals believe in ARGX or ROIV?

Is ARGX or ROIV more profitable?

Which has preferable earnings & valuation, ARGX or ROIV?

Do analysts prefer ARGX or ROIV?

Which has more risk and volatility, ARGX or ROIV?

Summary

How does Roivant Sciences compare to Revolution Medicines?

Which has stronger valuation and earnings, RVMD or ROIV?

Do institutionals & insiders hold more shares of RVMD or ROIV?

Is RVMD or ROIV more profitable?

Which has more risk and volatility, RVMD or ROIV?

Do analysts recommend RVMD or ROIV?

Does the media refer more to RVMD or ROIV?

Summary

How does Roivant Sciences compare to Natera?

Which has preferable earnings and valuation, ROIV or NTRA?

Does the media favor ROIV or NTRA?

Do insiders & institutionals have more ownership in ROIV or NTRA?

Do analysts rate ROIV or NTRA?

Which has more volatility and risk, ROIV or NTRA?

Is ROIV or NTRA more profitable?

Summary

How does Roivant Sciences compare to Biogen?

Does the media refer more to BIIB or ROIV?

Do analysts prefer BIIB or ROIV?

Do insiders & institutionals believe in BIIB or ROIV?

Which has stronger earnings & valuation, BIIB or ROIV?

Which has more volatility & risk, BIIB or ROIV?

Is BIIB or ROIV more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ROIV vs. The Competition

Roivant Sciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools